尼妥珠单抗
医学
鼻咽癌
单克隆抗体
表皮生长因子受体
放化疗
放射治疗
癌
内科学
单克隆
肿瘤科
癌症研究
抗体
免疫学
受体
作者
Renba Liang,Yang Liu,Xiaodong Zhu
标识
DOI:10.1177/1073274821989301
摘要
Epidermal growth factor receptor (EGFR) is highly expressed in most of Nasopharyngeal carcinoma (NPC) samples and is associated with poor outcomes. Therefore, targeting EGFR may be a promising strategy to improve patient prognosis. Nimotuzumab is a humanized anti-EGFR monoclonal antibody. Recently, accumulating evidence has demonstrated that combination nimotuzumab and induction chemotherapy, radiotherapy, or concurrent chemoradiotherapy confer benefits for patients with NPC. Moreover, the side effects of such regimes are tolerable. In this review, we focus on the current data of nimotuzumab in clinical trials in the treatment of NPC.
科研通智能强力驱动
Strongly Powered by AbleSci AI